TORNA ALL’ELENCO

Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study in European Journal of Cancer

2015
ASL Biella
ASL Vercelli

Tipo pubblicazione

Article

Autori/Collaboratori (200)Vedi tutti...

Baili P
Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, via Venezian 1, Milan, Italy
DI Salvo F
Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, via Venezian 1, Milan, Italy
Marcos-Gragera R
Epidemiology Unit, Girona Cancer Registry (Oncology Coordination Plan), Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute, Girona, Spain

et alii...

Abstract

Background: Overall survival after cancer is frequently used when assessing a health care service's performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case-mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based cancer registries, using complete and period approach. Results: Denmark, United Kingdom (UK) and Eastern European countries had lower survival than neighbouring countries. Five-year ACRS has been increasing throughout Europe, and substantial increases, between 1999-2001 and 2005-2007, have been achieved in countries where survival was lower in the past. Five-year ACRS for men and women are positively correlated with macro-economic variables like the Gross Domestic Product (GDP) and Total National Expenditure on Health (TNEH) (R2 about 70%). Countries with recent larger increases in GDP and TNEH had greater increases in cancer survival. Conclusions: ACRS serves to compare all cancer survival in Europe taking account of the geographical variability in case-mixes. The EUROCARE-5 data on ACRS confirm previous EUROCARE findings. Survival appears to correlate with macro-economic determinants, particularly with investments in the health care system.

DOI : 10.1016/j.ejca.2015.07.025

Keywords

age; Austria; Belgium; bladder cancer; breast cancer; Bulgaria; cancer localization; cancer patient; cancer registry; cancer survival; case mix; colon cancer; Croatia; Czech Republic; Denmark; Eastern European; economic aspect; esophagus cancer; Estonia; Europe; female; female genital tract cancer; Finland; France; gender; geography; Germany; gross national product; head and neck cancer; health care cost; human; Iceland; kidney cancer; larynx cancer; Latvia; Lithuania; liver cancer; lung cancer; major clinical study; male; Malta; melanoma; Netherlands; non-Hodgkin lymphoma; ovary cancer; pancreas cancer; Poland; population research; Portugal; primary tumor; priority journal; prostate cancer; rectum cancer; research; review; Slovakia; Spain; stomach cancer; Sweden; Switzerland; testis cancer; thyroid cancer; United Kingdom; uterine cervix cancer; uterus cancer;